JP2016503399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503399A5 JP2016503399A5 JP2015539782A JP2015539782A JP2016503399A5 JP 2016503399 A5 JP2016503399 A5 JP 2016503399A5 JP 2015539782 A JP2015539782 A JP 2015539782A JP 2015539782 A JP2015539782 A JP 2015539782A JP 2016503399 A5 JP2016503399 A5 JP 2016503399A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- cancer
- cetuximab
- administered
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718430P | 2012-10-25 | 2012-10-25 | |
| US61/718,430 | 2012-10-25 | ||
| PCT/US2013/066564 WO2014066606A2 (en) | 2012-10-25 | 2013-10-24 | Combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503399A JP2016503399A (ja) | 2016-02-04 |
| JP2016503399A5 true JP2016503399A5 (enExample) | 2016-12-08 |
Family
ID=50545472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539782A Pending JP2016503399A (ja) | 2012-10-25 | 2013-10-24 | 組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150273057A1 (enExample) |
| EP (1) | EP2911673A4 (enExample) |
| JP (1) | JP2016503399A (enExample) |
| KR (1) | KR20150070393A (enExample) |
| CN (1) | CN104812391A (enExample) |
| AU (1) | AU2013334599B2 (enExample) |
| BR (1) | BR112015009134A2 (enExample) |
| CA (1) | CA2889530A1 (enExample) |
| MX (1) | MX2015005307A (enExample) |
| RU (1) | RU2015119218A (enExample) |
| WO (1) | WO2014066606A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181243B2 (en) * | 2013-12-03 | 2015-11-10 | Hangzhou Pushai Pharmaceutical Technology Co. Ltd. | Solvate form M of trametinib dimethyl sulfoxide and methods of making and using thereof |
| BR112016011222A2 (pt) * | 2013-12-12 | 2017-09-19 | Novartis Ag | Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer |
| WO2016029002A2 (en) * | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | Growth factor receptor inhibitors |
| KR20170068409A (ko) | 2014-09-16 | 2017-06-19 | 이즈 참 리미티드 | 항-egfr 항체 및 그의 용도 |
| US20170027951A1 (en) * | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| JP2019513767A (ja) * | 2016-04-15 | 2019-05-30 | イーライ リリー アンド カンパニー | マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法 |
| MX387795B (es) * | 2016-06-03 | 2025-03-19 | Array Biopharma Inc | Combinaciones farmaceuticas. |
| RU2627692C1 (ru) | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| KR102260995B1 (ko) * | 2018-11-28 | 2021-06-04 | 국립암센터 | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| AU2021396395A1 (en) * | 2020-12-11 | 2023-07-27 | Erasca, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4163738B2 (ja) * | 2004-06-11 | 2008-10-08 | 日本たばこ産業株式会社 | 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物 |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| WO2008101840A1 (en) * | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
| AU2009210656A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| JP2013502236A (ja) * | 2009-08-24 | 2013-01-24 | ジェネンテック， インコーポレイテッド | Ｋｒａｓ変異及びｒｔｋ発現レベルを検出することによるｂ−ｒａｆ阻害剤治療に対する細胞の感受性の決定 |
| DK3560498T3 (da) * | 2009-10-16 | 2022-11-14 | Novartis Ag | Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer |
| CN105640964A (zh) * | 2010-04-21 | 2016-06-08 | 文蒂雷克斯药品公司 | 增强抗体依赖性细胞的细胞毒性的方法 |
| FR2968557A1 (fr) * | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| MY181439A (en) * | 2011-02-28 | 2020-12-22 | Sunshine Lake Pharma Co Ltd | Substituted quinoline compounds and methods of use |
| US20140134158A1 (en) * | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| TWI601725B (zh) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| RU2657749C2 (ru) * | 2012-09-21 | 2018-06-15 | Интенсити Терапьютикс, Инк | Способы лечения рака |
-
2013
- 2013-10-24 EP EP13848440.7A patent/EP2911673A4/en not_active Withdrawn
- 2013-10-24 CN CN201380056222.9A patent/CN104812391A/zh active Pending
- 2013-10-24 MX MX2015005307A patent/MX2015005307A/es unknown
- 2013-10-24 RU RU2015119218A patent/RU2015119218A/ru not_active Application Discontinuation
- 2013-10-24 BR BR112015009134A patent/BR112015009134A2/pt not_active IP Right Cessation
- 2013-10-24 AU AU2013334599A patent/AU2013334599B2/en not_active Ceased
- 2013-10-24 JP JP2015539782A patent/JP2016503399A/ja active Pending
- 2013-10-24 KR KR1020157013212A patent/KR20150070393A/ko not_active Ceased
- 2013-10-24 WO PCT/US2013/066564 patent/WO2014066606A2/en not_active Ceased
- 2013-10-24 CA CA2889530A patent/CA2889530A1/en not_active Abandoned
- 2013-10-24 US US14/437,231 patent/US20150273057A1/en not_active Abandoned